Skip to main navigation Skip to main content

OPEN ACCESS

- Current Issue
  
  Volume 32 Issue 2
  
  Ahead of Print
  
  Past Issues
  
  Editor-in-Chief : Won Kim
  
  Indexed In
  
  SCIE, MEDLINE, PubMed, PMC, and Scopus
Journal Insights
- 21.7
  
  Impact Factor
- 28.1
  
  Cite Score
- 7 days
  
  First Decision
- 4 days
  
  Publication after Acceptance
View all insights

Editor's Pick

Original Article

Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort
Jasmohan S. Bajaj, Patrick S. Kamath, Florence Wong, et al. Clin Mol Hepatol 2026;32(3):1321-1332.

Ahead of Print

Genetic and Genomic Insights Across the SLD Spectrum

Jake P. Mann, Karn Wijarnpreecha, Vitchapong Prasitsumrit, et al.
Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges

Shang-Chin Huang, Yi-Fen Shih, Chun-Jen Liu
Transitions from Combustible to Noncombustible Tobacco Use and Liver Outcomes in Steatotic Liver Disease

Eun Seok Kang, Su Kyoung Lee, Meng Sha, et al.

Current Issue

Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings
Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, et al. Clin Mol Hepatol 2026;32(2):443-463.
Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders
Yun Kyung Cho, Chang Hee Jung Clin Mol Hepatol 2026;32(2):464-486.
Burden of malnutrition and sarcopenia in patients with cirrhosis: pathophysiology, assessment, and management
Takao Miwa, Masahito Shimizu, Bernd Schnabl Clin Mol Hepatol 2026;32(2):487-510.

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA)

Won-Mook Choi, Ji Won Han, Tae Hyung Kim, et al.
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026

Do Seon Song, Jeong-Ju Yoo, Jeong Eun Song, et al.
2025 KASL clinical practice guidelines for management of hepatitis C

Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, et al.

Video abstract

The natural history and individualized prediction of liver stiffness-based fibrosis risk in metabolic dysfunction-associated steatotic liver disease
Yu Shi, Ruoqi Zhou, Seung Up Kim, et al. Clin Mol Hepatol 2026;32(3):1333-1348.
Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study
Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, et al. Clin Mol Hepatol 2026;32(2):737-750.
Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector
Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, et al. Clin Mol Hepatol 2026;32(1):239-257.

Snapshot

The hepatic portal area in homeostasis and disease

Fanrong Kong, Sara Lemoinne, Chantal Housset, et al.
Clin Mol Hepatol 2026;32(3):1467-1471.
Decoding platelet function in liver cirrhosis: A shift from quantity to quality

Vibhuti Jakhmola, Sukriti Baweja, Chhagan Bihari
Clin Mol Hepatol 2025;31(4):1384-1386.
Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, et al.
Clin Mol Hepatol 2025;31(3):1100-1102.

Most cited articles

Most viewed articles

Most downloaded articles